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Introduction {#sec1}
============

B cells with immunosuppressive capacity, known as regulatory B cells (Bregs), play an important role in restraining inflammation. In mice, regulatory function has been ascribed to IL-10-producing transitional type 2 marginal zone precursors (T2-MZPs) ([@bib10]), marginal zone (MZ) ([@bib13]) and CD1d^hi^CD5^+^B cells ([@bib71]), plasmablast ([@bib31]), and plasma cell ([@bib26]) populations. Bregs suppress inflammatory cytokine production by T cells and promote the differentiation of Foxp3^+^ regulatory T cells (Tregs), primarily via the secretion of interleukin-10 (IL-10) ([@bib6], [@bib46]). Mice lacking IL-10-expressing B cells develop exacerbated autoimmune arthritis and experimental autoimmune encephalitis (EAE) ([@bib6], [@bib12]), and adoptive transfer of IL-10-deficient B cells to arthritic mice fails to suppress inflammation ([@bib6]).

B cell receptor (BCR) engagement, Toll-like receptor (TLR) agonists lipopolysaccharide (LPS; TLR2 and TLR4) ([@bib24], [@bib60]), CpG oligo-deoxynucleotides (TLR9), and inflammatory cytokines such as IL-1β and IL-6 or IFN-α are all potent inducers of B cell-derived IL-10, suggesting an important role for Bregs in the restoration of tolerance after infection or inflammation ([@bib34], [@bib46]). Cell-derived signals arising from B and T lymphocyte cross-talk, including T cell-derived CD40L and IL-21, further support the expansion of Bregs ([@bib32], [@bib74]). Bregs, in turn, suppress inflammatory cytokine production by T cells and promote the differentiation of Foxp3^+^ regulatory T cells (Treg) ([@bib6], [@bib39], [@bib46]).

Unlike in murine T cells, in which it is well established that IL-10 expression is controlled by several transcription factors, including c-Maf and the aryl hydrocarbon receptor (AhR) ([@bib2]), there is limited knowledge of the transcriptional control of IL-10 production by Bregs. To date, studies of the molecular control of B cell IL-10 production have been limited to the examination of NFAT downstream of STIM1/STIM2 calcium sensors ([@bib30]) and Myd88 ([@bib27]) in mice and ERK ([@bib25]) and STAT3 ([@bib3]) in humans. More recently, Blimp1 and IRF4 ([@bib31]) have been linked to IL-10^+^ plasmablasts, but at least for Blimp1 and IRF4, neither transcription factor appeared to directly control the production of IL-10 by splenic B cells ([@bib31]).

To explore the molecular mechanisms regulating the differentiation of B cells into IL-10-producing Bregs, we used an IL-10-eGFP reporter mouse ([@bib28]). We compared the gene expression profiles of IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, IL-10eGFP^−^CD19^+^CD21^hi^CD24^hi^B cells, and IL-10eGFP^−^CD19^+^CD21^int^CD24^int^ follicular (FO) B cells isolated from arthritic mice (FO B cells do not produce IL-10 and do not suppress arthritis after adoptive transfer; [@bib10]). We chose to study IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs because this population contains both T2-MZP and MZ B cells, which together have been shown to contain the vast majority of splenic IL-10-producing Bregs ([@bib10], [@bib13]).

IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs have a unique transcriptome, characterized by a highly restricted cytokine/chemokine profile that distinguishes them from the IL-10eGFP^−^B cell subsets. AhR was among the most significant differentially expressed transcription factors in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, compared with both IL-10eGFP^−^CD19^+^CD21^hi^CD24^hi^B cells and IL-10eGFP^−^FO B cells. We show that AhR binds upstream to the transcription start site (TSS) of the *Il10* locus in IL-10eGFP^+^B cells but not in IL-10eGFP^−^B cells. LPS and anti-IgM, stimuli previously shown and confirmed here to induce the expression of AhR ([@bib63], [@bib66]), promote the differentiation of CD19^+^CD21^hi^CD24^hi^B cells (a population poised to become Bregs; [@bib10], [@bib30]) into IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs. Taking advantage of high-throughput sequencing, we demonstrated that activation of AhR under this Breg-polarizing condition results in the suppression of several pro-inflammatory cytokine and chemokine genes and in a highly restricted phenotype in CD19^+^CD21^hi^CD24^hi^B cells congruous with an immunosuppressive population.

*In vivo*, B cell-specific deletion of AhR caused exacerbated arthritis, reduced IL-10 production by CD19^+^CD21^hi^CD24^hi^Bregs, and reduced the frequency of Foxp3^+^Tregs and expansion of Th1 and Th17 cells. These results support a role of AhR in the differentiation of IL-10-producing Bregs and in the control of their immunosuppressive phenotype.

Results {#sec2}
=======

IL-10^+^ Bregs Present a Restricted Cytokine and Chemokine Gene Expression Profile {#sec2.1}
----------------------------------------------------------------------------------

To identify candidate genes that regulate the transcription of IL-10 in Bregs, arthritis was induced in IL-10eGFP reporter mice (Vert-x) ([@bib28]). We sorted splenic IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, IL-10eGFP^−^CD19^+^CD21^hi^CD24^hi^B cells, and IL-10eGFP^−^FO B cells (the two GFP^−^ populations are hereafter referred to as IL-10eGFP^−^B cell subsets) and profiled these cells using gene expression microarray ([Figures 1](#fig1){ref-type="fig"}A and 1B). Of note, very few IL-10-producing Bregs were present in the joint or draining lymph nodes (DLNs) of arthritic mice ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This sorting strategy was chosen to capture the majority of described Breg subsets, including IL-10^+^T2-MZP, IL-10^+^MZ, and IL-10^+^CD1d^hi^CD5^+^, which have been shown to exert suppressive capacity via IL-10 in this model of arthritis and in other models of autoimmunity ([@bib5], [@bib10], [@bib60], [@bib72]). Virtually no IL-10-expressing plasma cells or plasmablasts (LAG-3^+^ plasma cells \[[@bib26]\] and CD138^+^CD44^+^ plasmablasts \[[@bib31]\]) were detected in the spleen or DLNs following the induction of arthritis ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1H). The purity of sorted IL-10eGFP^+^ and IL-10eGFP^−^ subsets isolated for the microarray was more than 98% ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Principal-component analysis (PCA) revealed three distinct groups along the first dimension, with the IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Breg population clustered separately away from both IL-10eGFP^−^B cell subsets ([Figure 1](#fig1){ref-type="fig"}C). Analysis of gene expression revealed 1,073 differentially expressed genes (DEGs) between IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs and IL-10eGFP^−^CD19^+^CD21^hi^CD24^hi^B cells and 1,267 genes that were differentially expressed between IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs and IL-10eGFP^−^FO B cells (fold change \> 1.5 and adjusted p value \< 0.05) ([Figure S1](#mmc1){ref-type="supplementary-material"}J; [Figure 1](#fig1){ref-type="fig"}D).Figure 1Bregs Express a Highly Specific Cytokine and Chemokine Transcriptional ProfileAntigen-induced arthritis (AIA) was induced in IL-10eGFP reporter (Vert-X) mice.(A) Representative flow cytometry plots showing the frequency of CD19^+^CD21^hi^CD24^hi^ and CD19^+^CD21^int^CD24^int^(FO)B cells.(B) Representative flow cytometry plots showing the frequency of IL-10eGFP^+^ respectively in CD19^+^CD21^hi^CD24^hi^ and FO B cell subsets.(C) Principal-component analysis of transcripts in CD19^+^CD21^hi^CD24^hi^eGFP^+^, CD19^+^CD21^hi^CD24^hi^eGFP^−^, and FO B cell subsets (n = 3).(D) Heatmap showing the expression of genes by CD19^+^CD21^hi^CD24^hi^GFP^+^, CD19^+^CD21^hi^CD24^hi^GFP^−^, and FO B cells. Blue dashed line represents SD of 0.(E) Heatmaps showing the expression of cytokine (left) and chemokine (right) genes in the respective subsets.(F) Heatmaps of cytokine receptor (left) and chemokine receptor (right) expression profiles in the respective subsets (n = 3).(G) Log~2~ fold changes (FCs) of all significant genes identified in (E) and (F) for the GFP^+^ (left graph) and GFP^−^ (right graph) signatures. Log~2~ FCs are highlighted for GFP^+^ versus both GFP^−^ populations.All experiments were performed at day 7 post-IA injection. For (D)--(F), heatmaps show *Z* scores based on normalized GeneChip robust multiarray averaging (GC-RMA) values. Listed genes highlighted in red are upregulated in the CD19^+^CD21^hi^CD24^hi^eGFP^+^ population compared with CD19^+^CD21^hi^CD24^hi^eGFP^−^ (adjusted p value \< 0.05). In (A) and (B), data are representative of at least five independent experiments.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

In the context of arthritis, splenic Bregs have been shown to produce mainly IL-10 ([@bib45]). Of the cytokine genes upregulated in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, only *Il10* and *Ebi3* reached an adjusted p value of \< 0.05, compared with both IL-10eGFP^−^ B cell subsets. However, because *Il12a* was not found to be upregulated in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, we excluded a role of IL-35 in these cells. Although a trend in the increase of transcripts for pro-inflammatory genes such as *Il1a*, *Il12b*, *Il15*, and *Il18* was noted, the expression of these genes was not significantly different from the IL-10eGFP^−^B cell subsets ([Figure 1](#fig1){ref-type="fig"}E). IL-10eGFP^−^FO B cells, which unlike CD19^+^CD21^hi^CD24^hi^B cells do not suppress inflammation on adoptive transfer ([@bib10]), express a different transcriptional profile, characterized by higher expression of cytokines and cytokine receptors known to mediate inflammatory responses, compared with IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs ([Figures 1](#fig1){ref-type="fig"}E and 1F). The transcripts that were significantly differentially expressed in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs versus IL-10eGFP^−^B cell subsets are summarized in ([Figure 1](#fig1){ref-type="fig"}G). In keeping with the anti-inflammatory role of Bregs, we found that the Th2-attracting chemokines *Ccl17* and *Ccl22* ([@bib16], [@bib36]), and the chemokine receptor *Cxcr3*, important for the trafficking of lymphocytes to the synovium in arthritis ([@bib35]), were upregulated in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs compared with IL-10eGFP^−^B cell subsets ([Figures 1](#fig1){ref-type="fig"}E--1G). These results showed that in the context of arthritis, splenic Bregs displayed a distinct anti-inflammatory transcriptional profile compared with IL-10eGFP^−^B cell subsets.

AhR Is Highly Expressed in IL-10-Producing Bregs {#sec2.2}
------------------------------------------------

To screen for molecules involved in IL-10 transcription and Breg function, genes concordant for comparison 1 (between IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs and IL-10eGFP^−^FO B cells) and comparison 2 (between IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs and IL-10eGFP^−^CD19^+^CD21^hi^CD24^hi^B cells) ([Figure S1](#mmc1){ref-type="supplementary-material"}K) were filtered on the basis of the transcription factor Gene Ontology term, resulting in 23 candidates ([Figure 2](#fig2){ref-type="fig"}A). Pathway analyses showed that AhR represented a central network hub ([Figure 2](#fig2){ref-type="fig"}B) and was the most significantly enriched candidate in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs (adjusted p value \< 3.34 × 10^−5^; [Table S1](#mmc1){ref-type="supplementary-material"}; [Figure S1](#mmc1){ref-type="supplementary-material"}L). Analysis of transcription factors previously shown to be associated with IL-10 transcriptional regulation in other lymphocyte subsets, including Tregs ([@bib17]), confirmed that AhR was the most significantly upregulated IL-10-related transcription factors in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, in comparison with IL-10eGFP^−^B cell subsets ([Figure 2](#fig2){ref-type="fig"}C). Microarray signal intensities for *Il10* and *Ahr* were higher in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs compared with IL-10eGFP^−^B cell subsets ([Figure 2](#fig2){ref-type="fig"}D). qPCR analysis confirmed that *Il10* and *Ahr* mRNA expression was higher in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs than in both IL-10eGFP^−^B cell subsets ([Figures 2](#fig2){ref-type="fig"}E and 2F). Corroborating the results in [Figures 2](#fig2){ref-type="fig"}E and 2F, assay for transposase-accessible chromatin using sequencing (ATAC-seq) showed increased accessibility in both the *Il10* and *Ahr* loci in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs, in comparison with both IL-10eGFP^−^B cell subsets ([Figure 2](#fig2){ref-type="fig"}G).Figure 2Identification of AhR as a Key IL-10 Associated Transcription Factor in BregsAntigen-induced arthritis (AIA) was induced in IL-10eGFP reporter mice.(A) Heatmap showing *Z* scores of significant DEG (n = 23, adjusted p value \< 0.05) based on normalized GC-RMA values, filtered on transcription factor activity Gene Ontology terms in sorted CD19^+^CD21^hi^CD24^hi^eGFP^+^, CD19^+^CD21^hi^CD24^hi^eGFP^−^, and FO B cells.(B) Ingenuity pathway network analysis identifies a cluster of genes with AhR as the central hub. The lines between genes represent known interactions (solid lines represent direct interactions, dashed lines represent indirect interactions).(C) Heatmap of *Z* scores of transcription factors regulating IL-10, expressed by CD19^+^CD21^hi^CD24^hi^eGFP^+^, CD19^+^CD21^hi^CD24^hi^eGFP^−^, and FO B cells. Genes highlighted in red are upregulated in the CD19^+^CD21^hi^CD24^hi^GFP^+^ population compared with eGFP^−^ populations. Black asterisks, adjusted p value \< 0.05 for the comparison of CD19^+^CD21^hi^CD24^hi^eGFP^+^ versus FO eGFP^−^. Red asterisks, adjusted p value \< 0.05 for the comparison of CD19^+^CD21^hi^CD24^hi^eGFP^+^ versus CD19^+^CD21^hi^CD24^hi^eGFP^−^.(D) Microarray signal intensities of *Il10* and *Ahr* (n = 3).(E and F) Validation of (E) *Il10* and (F) *Ahr* mRNA expression in the indicated B cell subsets by qPCR (n = 3).(G) Representative ATAC-seq tracks for the *Il10* and *Ahr* loci in CD19^+^CD21^hi^CD24^hi^eGFP^+^, CD19^+^CD21^hi^CD24^hi^eGFP^−^, and FO B cells (n = 3). Track heights between samples are normalized through group autoscaling. For qPCR, gene expression was calculated normalizing to β-actin.All experiments were performed at day 7 post-IA injection. In (D)--(F), data are expressed as mean ± SEM. In (E) and (F), data are representative of three independent experiments with biological replicates. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001, one- and two-way ANOVA.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

AhR Upregulation Promotes the Generation of IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs {#sec2.3}
--------------------------------------------------------------------------------

We and others have recently shown that BCR signals combined with TLR stimulation induce a substantial upregulation of AhR in B cells ([@bib63], [@bib66]). Because BCR signals together with TLR engagement are known to be pivotal in the generation of Bregs ([@bib45]), next we investigated whether the differentiation of Bregs "marked" by the induction of IL-10 expression by these stimuli was AhR dependent. For this purpose, CD19^+^CD21^hi^CD24^hi^B cells were sorted from the spleens of arthritic mice and stimulated with LPS ± anti-IgM. An 11-fold increase in the frequency of IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs and a 200-fold increase in the production of IL-10 by CD19^+^CD21^hi^CD24^hi^Bregs were observed upon LPS+anti-IgM stimulation compared with unstimulated cells ([Figures 3](#fig3){ref-type="fig"}A--3C). Increased levels of AhR expression in IL-10^+^CD19^+^CD21^hi^CD24^hi^ Bregs compared with IL-10^−^FO and IL-10^−^CD19^+^CD21^hi^CD24^hi^B cells were confirmed using flow cytometry ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). We established the kinetics of AhR and AhR pathway-associated gene expression in relation to *Il10* transcription, after activation with Breg-polarizing stimuli. We observed a peak in the expression of *Ahr* and *Cyp1a1* (the gene encoding the AhR-dependent cytochrome P4501A1) at 6 h post-stimulation with LPS+anti-IgM, followed by an upregulation of AhR repressor (*Ahrr*) and *Il10* at 24 h. No significant changes in the expression of the AhR binding partner AhR nuclear translocator (*Arnt*) were observed ([Figures 3](#fig3){ref-type="fig"}D--3H). Of note, *ex vivo* CD19^+^CD21^hi^CD24^hi^B cells display higher expression of *Ahr* (confirmed at the protein level using flow cytometry and western blotting), *Il10, Cyp1a1*, *Ahrr*, and *Arnt* compared with FO B cells ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2J). Together these data show that IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs express the highest levels of AhR compared with the IL-10^−^CD19^+^CD21^hi^CD24^hi^ and IL-10^−^FO B cells and that in CD19^+^CD21^hi^CD24^hi^B cells, AhR upregulation precedes the production of IL-10.Figure 3The Effect of AhR in the Differentiation of CD19^+^CD21^hi^CD24^hi^ into BregsAntigen-induced arthritis (AIA) was induced in IL-10eGFP reporter or C57BL/6 mice.(A and B) Representative flow cytometry plots (A) and bar chart (B) showing the percentage of IL-10 expression in CD19^+^CD21^hi^CD24^hi^B cells (n = 5). In these experiments, CD19^+^CD21^hi^CD24^hi^B cells were stimulated for 24 h with LPS, followed by an additional 24 h with anti-IgM.(C) IL-10 production, as measured by ELISA (n = 7).(D--H) CD19^+^CD21^hi^CD24^hi^B cells were isolated from WT C57BL/6 mice and stimulated for 6 or 24 h with LPS+anti-IgM. The mRNA levels of (D) *Ahr*, (E) *Cyp1a1*, (F) *Ahrr*, (G) *Arnt*, and (H) *Il10* were analyzed *ex vivo* and after stimulation (n = 3).(I) IL-10 production measured by ELISA in LPS+anti-IgM-stimulated CD19^+^CD21^hi^CD24^hi^B cells and FO B cells (n = 4 per group).(J) CpGb-stimulated CD19^+^CD21^hi^CD24^hi^ and FO B cells from *Ahr*^*+/−*^ and *Ahr*^*−/−*^ mice co-cultured for 72 h with anti-CD3 stimulated autologous CD4^+^T cells from *Ahr*^*+/−*^ mice. Representative flow cytometry plots showing the frequency of IFN-γ^+^CD4^+^ T cell.(K) Bar chart showing percentage suppression of IFN-γ^+^CD4^+^ T cells by splenic CD19^+^CD21^hi^CD24^hi^B cells or FO B cells following stimulation with anti-CD3 (n = 3).(L) CD19^+^CD21^hi^CD24^hi^ and FO B cells were stimulated for 6 h with either vehicle alone (DMSO) or the AhR agonist FICZ, and the expression of *Cyp1a1* and *Il10* was measured using qRT-PCR (n = 3).(M) Jaspar binding motif analysis of putative AhR binding sites (XRE sites) in 500 bp regions of DNA, upstream of the *Il10* TSS.(N) Schematic representing the experimental design for the ChIP-qPCR assay. Briefly, we isolated splenic B cells from IL-10eGFP reporter mice and stimulated them for 24 h with LPS, followed by 24 h with anti-IgM+FICZ.(O) ChIP analysis of AhR binding to the *Il10* locus was performed in IL-10eGFP^+^CD19^+^ and IL-10eGFP^−^CD19^+^ B cells. Bar chart showing the relative enrichment of AhR binding to regions upstream/downstream or in the promoters (labeled as P) of *Il10*, *Cyp1a1*, and *Gapdh* (n = 3). For qPCR, gene expression was calculated normalizing to β-actin.All experiments were performed at day 7-post-IA injection. Data representative of at least three independent experiments with biological replicates. In (B)--(I), (K), (L), and (O), data are expressed as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001, one- and two-way ANOVA.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To understand the role of AhR in the regulation and function of IL-10 expression in CD19^+^CD21^hi^CD24^hi^Bregs, we isolated CD19^+^CD21^hi^CD24^hi^B cells and FO B cells from *Ahr*^+/−^ and *Ahr*^*−/−*^ mice and stimulated them *in vitro* with LPS+anti-IgM. Lack of AhR significantly reduced the ability of CD19^+^CD21^hi^CD24^hi^B cells to differentiate into IL-10-producing CD19^+^CD21^hi^CD24^hi^Bregs compared with AhR competent CD19^+^CD21^hi^CD24^hi^B cells ([Figure 3](#fig3){ref-type="fig"}I). In addition, *Ahr*^*−/−*^ CD19^+^CD21^hi^CD24^hi^B cells presented a reduced capacity to inhibit IFN-γ production by CD4^+^T cells *in vitro* compared with *Ahr*^*+/−*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figures 3](#fig3){ref-type="fig"}J and 3K). FO B cells failed to produce IL-10 and to suppress IFN-γ by CD4^+^ T cells, irrespective of AhR expression ([Figures 3](#fig3){ref-type="fig"}I--3K).

To assess if activation of AhR directly with endogenous ligands promotes the differentiation of CD19^+^CD21^hi^CD24^hi^B cells into IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs, we stimulated sorted CD19^+^CD21^hi^CD24^hi^B cells or FO B cells with the AhR ligand 6-formylindolo(3,2-b) carbazole (FICZ). AhR activation significantly upregulated the expression of *Cyp1a1* and *Il10* in the CD19^+^CD21^hi^CD24^hi^B cell subset but not in FO B cells compared with the vehicle control ([Figure 3](#fig3){ref-type="fig"}L). Secretion of IL-10 was further enhanced by the addition of FICZ to LPS+anti-IgM-stimulated CD19^+^CD21^hi^CD24^hi^B cells, compared with LPS+anti-IgM alone ([Figure S2](#mmc1){ref-type="supplementary-material"}K). An increase in Breg IL-10 expression was observed when CD19^+^CD21^hi^CD24^hi^B cells were cultured in Iscove's modified Dulbecco's medium (IMDM; enriched in aromatic amino acids that give rise to AhR ligands; [@bib65]) ([@bib15]) compared with RPMI media ([Figure S2](#mmc1){ref-type="supplementary-material"}L).

We next investigated whether AhR regulates IL-10 expression in IL-10eGFP^+^CD19^+^CD21^hi^CD24^hi^Bregs by directly binding the *Il10* locus. To address this, we took advantage of the JASPAR tool ([@bib21]) and identified putative AhR binding sites in 500 bp regions up to −5 kb upstream and +5 kb downstream of the *Il10* TSS and designed primer probes to span these regions ([Figure 3](#fig3){ref-type="fig"}M). We sorted IL-10eGFP^+^ and IL-10eGFP^−^B cells, after stimulation with LPS+anti-IgM+FICZ (the combination of stimuli was used to maximize AhR activation and translocation to the nucleus) and performed chromatin immunoprecipitation (ChIP) qPCR on AhR-bound DNA ([Figure 3](#fig3){ref-type="fig"}N). Significantly enriched AhR binding was observed at −3.5 kb upstream of the *Il10* TSS in the IL-10eGFP^+^ population. Minimal binding of AhR was observed in other regions of the *Il10* locus. As a positive control, we confirmed that under these experimental conditions, there was enriched binding of AhR to the promoter of *Cyp1a1* but no binding to *Gapdh,* an AhR-independent housekeeping gene ([Figure 3](#fig3){ref-type="fig"}O). These results show that AhR controls IL-10 transcription and the function of Bregs.

AhR Controls the Breg Transcriptional Program by Suppressing Pro-inflammatory Gene Expression {#sec2.4}
---------------------------------------------------------------------------------------------

To examine the role of AhR in controlling the differentiation of CD19^+^CD21^hi^CD24^hi^B cells into Bregs, and to ascertain the relative contribution of AhR in establishing the restricted Breg phenotype identified in the microarray ([Figures 1](#fig1){ref-type="fig"}E--1G) in addition to IL-10 production, we took advantage of mice with a B cell-specific deficiency of AhR (*Ahr*^*fl/−*^*Mb1*^*cre/+*^) ([@bib66])) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). The use of these mice avoids any cell extrinsic effects of AhR that could indirectly influence Breg differentiation ([@bib55]). CD19^+^CD21^hi^CD24^hi^B cells were sorted from immunized *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice, and the transcriptional profile of sorted CD19^+^CD21^hi^CD24^hi^B cells was compared before and after stimulation under Breg-polarizing conditions (LPS+anti-IgM). Both the normalized counts for *Ahr* and the accessibility of the *Ahr* locus measured by ATAC-seq increased in LPS+anti-IgM-stimulated *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells compared with *ex vivo Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Signaling pathway impact analysis (SPIA) of DEGs revealed overrepresented pathways relating to cytokine-cytokine receptor interactions and chemokine signaling in stimulated *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells versus *ex vivo Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figure 4](#fig4){ref-type="fig"}A). Analysis of the genes differentially expressed within this pathway confirmed that under Breg-polarizing conditions, several genes identified in the IL-10eGFP^+^ signature (as shown in [Figure 1](#fig1){ref-type="fig"}G), including *Il10*, *Ccl22*, and *Il2ra*, were upregulated, while those associated with the IL-10eGFP^−^ signature, including *Il12a*, *Il10ra*, and *Ltb*, were downregulated under Breg-polarizing conditions ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 4AhR Suppresses Pro-inflammatory Gene Expression during the Differentiation of BregsAIA was induced in *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice.(A) Signaling pathway impact analysis (SPIA) showing the top significant (p \< 0.05) over-represented and under-represented pathways in LPS+anti-IgM-stimulated compared with *ex vivo* CD19^+^CD21^hi^CD24^hi^B cells from *Mb1*^*cre/+*^ mice. The total perturbation accumulation of these pathways (tA) score is represented on the x axis.(B) Volcano plot of RNA-seq analysis showing log~2~ fold changes (FCs) between LPS+anti-IgM-stimulated compared with *ex vivo* CD19^+^CD21^hi^CD24^hi^B cells from *Mb1*^*cre/+*^ mice, plotted against --log~10~ p value for the cytokine-cytokine receptor interaction pathway. Red dots represent significant DEG, with the red line denoting a cut-off p value of \< 0.05.(C) Signaling pathway impact analysis (SPIA) showing the top significant (p \< 0.05) over-represented and under-represented pathways in 6 h LPS+anti-IgM-stimulated CD19^+^CD21^hi^CD24^hi^B cells from *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice compared with *Mb1*^*cre/+*^ mice.(D) Volcano plot of RNA-seq analysis showing log~2~ fold changes (FCs) between LPS+anti-IgM-stimulated CD19^+^CD21^hi^CD24^hi^B cells from *Ahr*^*fl/−*^*Mb1*^*cre/+*^ versus *Mb1*^*cre/+*^ mice, plotted against --log~10~ p value for the cytokine-cytokine receptor interaction pathway.(E) CD19^+^CD21^hi^CD24^hi^B cells were isolated from *Mb1*^*cre/+*^ mice and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice, stimulated for 6 h with LPS+anti-IgM, and assessed for mRNA levels of *Il2*, *Il6*, *Tnf*, *Ccl22*, and *Il5ra* (n = 4).(F) IL-2, IL-6, and TNFα concentrations from 48 h LPS+anti-IgM-stimulated CD19^+^CD21^hi^CD24^hi^ B cells from *Mb1*^*cre/+*^ mice and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 4).(G) Volcano plot of ATAC-seq DARs in genes taken from the cytokine-cytokine receptor interaction pathway, comparing chromatin accessibility at these sites between *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre*^ CD19^+^CD21^hi^CD24^hi^ B cells after 6 h LPS+anti-IgM. For qPCR, gene expression was calculated normalizing to β-actin.All experiments were performed at day 7 post-IA injection. For RNA-seq data, n = 3 per condition and genotype. For ATAC-seq data, n = 3 for *Mb1*^*cre/+*^ mice and n = 2 for *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice. For (E) and (F), data are representative of two independent experiments with biological replicates, and data are expressed as mean ± SEM. ^∗^p \< 0.05, Mann-Whitney test.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

A signature of genes related to cytokine-cytokine receptor interaction was upregulated in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^ B cells under LPS+anti-IgM stimulation compared with *Mb1*^*cre/+*^ ([Figure 4](#fig4){ref-type="fig"}C). Forty-four of 102 genes in this pathway were significantly differentially expressed between *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). Of the genes that were differentially expressed under Breg-polarizing conditions ([Figure 4](#fig4){ref-type="fig"}B), pro-inflammatory cytokines including *Il6*, *Tnf*, *Il2*, and chemokines such as *Ccl3*, *Ccl5*, and *Cxcl16*, known to recruit lymphocytes to the inflamed synovia in models of arthritis ([@bib19], [@bib48], [@bib56], [@bib58]), were upregulated in the absence of AhR ([Figure 4](#fig4){ref-type="fig"}D). The absence of AhR expression led to downregulation of the *Il5ra* gene, which had previously been associated with Breg function ([@bib23]), *Ccl22*, and *Il18*, which we have identified as Breg-associated genes in the microarray. Testing key arthritogenic pro-inflammatory transcripts ([@bib11], [@bib38], [@bib59]) using qPCR confirmed that *Il2*, *Il6*, and *Tnf* were increased in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells, and *Ccl22* and *Il5ra* were decreased compared with *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells. The increase in pro-inflammatory cytokines in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells was confirmed using ELISA ([Figures 4](#fig4){ref-type="fig"}E and 4F).

Specific interrogation of differentially accessible regions (DARs) in loci encoding genes from the cytokine-cytokine receptor interaction pathway revealed an overall decrease in chromatin accessibility in these genes in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells. Seventy-eight DARs (p \< 0.05) were identified among the genes regulated by AhR at the transcriptional level, including *Il2*, *Il6*, *Ccl3*, *Ccl5*, *Il5ra*, *Ccl22*, and *Il10* between LPS+anti-IgM polarized *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figure 4](#fig4){ref-type="fig"}G).

To confirm that AhR suppresses pro-inflammatory gene expression during the development of Bregs, we blocked AhR signaling *in vitro* with CH-223191. Concordant with the results identified with RNA sequencing (RNA-seq), blocking AhR signaling resulted in upregulation of *Il6* and *Tnf* and downregulation of *Il10* and *Ccl22* mRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

AhR can repress gene expression indirectly by controlling the activity of additional molecules involved in gene regulation, including genes related to the NF-κB pathway. Because we have previously shown that the NF-κB pathway is linked to IL-10 production in Bregs ([@bib46]), next we analyzed the effect that the lack of AhR in B cells had on the NF-κB pathway in LPS+anti-IgM-stimulated cells. A reduction in NF-κB pathway-related genes, including *Cd40* and *Myd88*, required for IL-10 production, was observed in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells. This was mirrored by upregulation of genes relating to inflammation (*Tnf*, *Tnfaip3*, *Ccl4*, and *Il1r1*) in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ compared with *Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

Our data suggest that AhR contributes the Breg transcriptional program by suppressing pro-inflammatory gene expression. To rule out whether this effect is secondary to the decrease in IL-10, we cultured wild-type (WT) and *Il10r*^−/−^ CD19^+^CD21^hi^CD24^hi^B cells with LPS+anti-IgM in the presence or absence of the selective AhR antagonist CH-223191. The expression of *Il6* and *Tnf* was significantly increased in both WT and IL-10R^−/−^ CD19^+^CD21^hi^CD24^hi^B cells cultured with the AhR antagonist, suggesting a direct effect of AhR in the suppression of pro-inflammatory gene expression ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Collectively, these data show that under Breg-polarizing conditions, AhR acts as a molecular switch that "turns off" a number of pro-inflammatory cytokines and chemokines in CD19^+^CD21^hi^CD24^hi^B cells, while promoting the expression of IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg-associated cytokines and receptors.

B Cell-Specific AhR Deficiency Causes Exacerbated Arthritis and Increased T Cell-Driven Arthritogenic Responses {#sec2.5}
---------------------------------------------------------------------------------------------------------------

Having confirmed the contribution of AhR in the programming of the IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg transcriptional profile, we explored the impact of AhR deficiency specifically in B cells on the immune response associated with arthritis. *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice developed exacerbated arthritis compared with control *Mb1*^*cre/+*^ mice ([Figure 5](#fig5){ref-type="fig"}A). Histological analysis of joint tissue showed an increase in immune cell infiltration in the synovia and hyper-vascularization in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ compared with control *Mb1*^*cre/+*^ mice ([Figure 5](#fig5){ref-type="fig"}B). The enhanced inflammation was associated with a significant increase in the frequency and number of IFN-γ- and IL-17-expressing CD4^+^ T cells in the spleen and DLN ([Figures 5](#fig5){ref-type="fig"}C--5F). *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice had an increased frequency and number of IL-17^+^CD4^+^ cells and a reduction in the frequency and total number of Foxp3^+^Tregs in the inguinal DLN compared with the control mice ([Figures 5](#fig5){ref-type="fig"}F--5H). Increased levels of IL-17 were observed in the synovium of inflamed joints of *Ahr*^*fl/−*^*Mb1*^*cre/+*^ compared with the control group, whereas IFN-γ levels were undetectable ([Figure 5](#fig5){ref-type="fig"}I).Figure 5B Cell AhR Deficiency Exacerbates Antigen Induced Arthritis(A) Mean clinical score of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice following induction of arthritis; y axis shows percentage swelling in antigen-injected knee compared with control knee (n = 12 per group).(B) Representative H&E staining of arthritic joints from *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 3; original magnification of 20×). Arrows indicate hyper-vascularization. Scale bar, 100 μM.(C--H) Representative flow cytometry plots and bar charts showing respectively the percentage and number of (C and D) IFN-γ^+^CD4^+^ cells, (E and F) IL-17^+^CD4^+^ cells, and (G and H) Foxp3^+^CD4^+^T cells in the spleens and DLNs of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 7).(I) IL-17 concentration as measured in the synovial fluid of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 6).(J) Schematic showing the experimental design of the adoptive transfer system.(K) Mean clinical score of C57BL/6 mice following adoptive transfer of CD19^+^CD21^hi^CD24^hi^B cells purified from *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice, administered on the day of disease onset. Control (no transfer) group received PBS (n = 5).(L) Bar charts showing respectively the percentage of IFN-γ^+^CD4^+^ cells and IL-17^+^CD4^+^ cells in the spleens of WT recipient mice, following an adoptive transfer of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells or a PBS control (n = 5).All experiments were performed at day 7 post-IA injection. Data are representative of at least three independent experiments with biological replicates. In (A), (D), (F), (H), (I), (K), and (L), data are expressed as mean ± SEM. ^∗^p \< 0.05 and ^∗∗^p \< 0.01, one- and two-way ANOVA and Mann-Whitney test.

Adoptive transfer of *Mb1*^*cre/+*^ or *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells into syngeneic mice showed that only CD19^+^CD21^hi^CD24^hi^B cells from *Mb1*^*cre/+*^, but not from *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice, significantly inhibited disease and Th17/Th1 differentiation in the recipient mice ([Figures 5](#fig5){ref-type="fig"}J--5L), confirming that CD19^+^CD21^hi^CD24^hi^B cells were less effective at suppressing inflammation in the absence of AhR.

*Ahr*^*fl/−*^*Mb1*^*cre/+*^ Mice Do Not Have a Defect in B Cell Development but Present with a Reduced Frequency and Number of Bregs {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------------

To establish that the increase in disease severity and the impact on the T cell compartment was due to the lack of AhR-expressing Bregs, rather than a consequence of abnormal B cell development, we next compared the frequencies of pro, pro-pre, pre, immature, transitional (T), early, and late mature B cells in the bone marrow or T1 or FO B cells in the spleens of *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ mice. We observed no differences in these populations, suggesting that the increase in arthritis severity and in pro-inflammatory T cells was indeed due to a reduction of CD19^+^CD21^hi^CD24^hi^Bregs rather than a consequence of abnormal B cell development ([Figures 6](#fig6){ref-type="fig"}A and 6B; [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5H). In line with previous findings showing that AhR represses differentiation of B cells into plasma cells ([@bib61]), we found increased frequencies of splenic plasma cells ([Figures S5](#mmc1){ref-type="supplementary-material"}I and S5J) and increased *Prdm1* mRNA expression in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ B cells relative to *Mb1*^*cre/+*^ B cells ([Figure S5](#mmc1){ref-type="supplementary-material"}K). Despite changes in the frequency of plasma cells in the spleens, there were no differences in the amounts of secreted IgG, IgM, and IgA in the serum of arthritic *Ahr*^*fl/−*^*Mb1*^*cre/+*^ versus *Mb1*^*cre/+*^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}L).Figure 6CD19^+^CD21^hi^CD24^hi^B Cells in *Ahr*^*fl/−*^*Mb1*^*cre/+*^ Mice Are Less Able to Differentiate into BregsAIA was induced in *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice.(A) Representative flow cytometry plots showing percentage and (B) bar charts showing the percentages and absolute numbers of CD19^+^CD21^−^CD24^hi^ (T1), CD19^+^CD21^hi^CD24^hi^, and FO B cells in the spleens of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 7).(C) CD19^+^CD21^hi^CD24^hi^ or FO B cells were sorted from *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice and stimulated with LPS+anti-IgM for 48 h. IL-10 production, as measured by ELISA (n = 4 per group).(D and E) Representative flow cytometry plots (D) showing percentage and (E) bar charts showing percentages and absolute numbers of CD19^+^CD21^−^CD24^hi^, CD19^+^CD21^hi^CD24^hi^ and FO B cells in the MLNs of *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice (n = 7).(F) CD19^+^B cells were sorted from *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice and stimulated with LPS+anti-IgM for 48 h. IL-10 production, as measured by ELISA (n = 3).All experiments were performed at day 7 post-IA injection. Data representative of at least two independent experiments with biological replicates. In (B), (C), (E), and (F), data are expressed as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.01, two-way ANOVA and Mann-Whitney test.See also [Figures S5--S7](#mmc1){ref-type="supplementary-material"}.

Although there were no differences in the number of splenic CD19^+^CD21^hi^CD24^hi^B cells between the two groups, *Ahr*^*fl/−*^*Mb1*^*cre/+*^CD21^hi^CD24^hi^B cells secreted significantly less IL-10 than *Mb1*^*cre/+*^CD19^+^CD21^hi^CD24^hi^B cells, following stimulation with LPS+anti-IgM ([Figure 6](#fig6){ref-type="fig"}C). IL-10 production by *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^B cells was significantly reduced in response to TLR9 stimulation ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C). Comparable levels of *Ebi3* and *Il12a* were present in B cells from *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice and *Mb1*^*cre/+*^ mice ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). These results, together with our previous findings showing a redundant effect of IL-35 in Bregs in this model ([@bib64]), excluded that Bregs were non-functional because of a lack of IL-35 production in the absence of AhR.

The observed IL-10 reduction was not due to impaired B cell proliferation, as an equivalent expression of Ki*-*67 in *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells was observed both directly *ex vivo* after antigen-induced arthritis (AIA) and after stimulation with LPS+anti-IgM ([Figures S6](#mmc1){ref-type="supplementary-material"}F--S6I). No difference in genes related to the cell cycle was observed, including *Ccno*, previously been shown to be regulated by AhR in splenic B cells ([@bib66]), between *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells ([Figure S6](#mmc1){ref-type="supplementary-material"}J), suggesting that there was no impairment in BCR-driven regulation of B cell entry into the cell cycle ([@bib41]).

Mesenteric lymph nodes (MLNs) are important sites for the licensing of Breg development, through the exposure to microbiota-derived pro-inflammatory signals IL-1β and IL-6 ([@bib46]). Fewer CD19^+^CD21^hi^CD24^hi^B cells, and a decreased amount of B cell-derived IL-10 after *in vitro* polarization with LPS+anti-IgM, were observed in the MLN of *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice compared with control *Mb1*^*cre/+*^ mice ([Figures 6](#fig6){ref-type="fig"}D--6F). Of interest, no difference in gut-homing integrin α4β7 expression was observed in splenic or MLN-derived CD19^+^CD21^hi^CD24^hi^B cells between *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ mice, suggesting that the reduction of Bregs observed in the MLN of *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice is α4β7 independent ([Figures S6](#mmc1){ref-type="supplementary-material"}K--S6M). We can exclude that the decreased frequency of Bregs was the consequence of a reduction in monocyte-derived lL-1β and IL-6 produced in the spleens or in the MLNs, as equivalent amounts of these cytokines were produced by these cells in both *Ahr*^*fl/−*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ mice ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7D).

Thus, our results collectively show that mice lacking AhR expression in B cells phenocopy the results we have previously observed in mice with IL-10^−/−^B cells ([@bib6]) and influence IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg differentiation in a cell-intrinsic manner.

Discussion {#sec3}
==========

Bregs are generated in the periphery in response to a variety of "homeostatic" inflammatory stimuli including activation through TLRs and by pro-inflammatory cytokines ([@bib45]). The transcriptional program that governs the differentiation and function of IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs remains virtually unknown. Here, we show that AhR contributes to the differentiation of CD19^+^CD21^hi^CD24^hi^B cells into functionally suppressive IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs by regulating their IL-10 production and by repressing the transcription of pro-inflammatory mediators. The importance of IL-10 in mediating the suppressive effect of Bregs is well established, and its role is corroborated by *in vivo* results showing that mice lacking IL-10-producing B cells develop exacerbated autoimmunity ([@bib6]). Similarly, AhR deficiency restricted to B cells impairs IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg differentiation and function, resulting in an increase of IFNγ and IL-17-expressing CD4^+^ T cells, a decrease in Tregs, and the development of an exacerbated arthritis.

AhR plays a pleiotropic role in the regulation of several immune responses ([@bib55]), most notably in the differentiation of CD4^+^ T cells, in which AhR influences both the differentiation and activation of Th17 cells, which are known to play a major role in the pathogenesis of several autoimmune diseases ([@bib54]) and the differentiation of CD4^+^ T cells into Tr1 cells ([@bib2]). Immune suppression was one of the earliest known observations of AhR function. 2,3,7,8-Tetrachlorodibenzo-ρ-dioxin (TCDD), an environmental contaminant and a potent AhR agonist, was found to suppress delayed hypersensitivity (DTH) responses to tuberculin ([@bib67]). More recently, it has become apparent that AhR has a conserved role in the regulation of IL-10 across the innate and adaptive immune system, controlling IL-10 production in natural killer cells ([@bib68]), peritoneal ([@bib22]) and bone marrow-derived macrophages ([@bib53]), and Tr1 cells, in which AhR binding to the *Il10* promoter region has been described ([@bib2]). We demonstrate that in IL-10^+^B cells, AhR binds upstream of the *Il10* TSS to a different genomic region than in Tr1 cells, suggesting that there are cell context- and cell signal-specific epigenetic differences in the regulation of *Il10* ([@bib50]).

An interesting finding in our study was the discovery that AhR partly controls the differentiation of CD19^+^CD21^hi^CD24^hi^B cells into a polarized IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg population that produces only IL-10 by contributing to IL-10 induction and by suppressing the transcription of several pro-inflammatory cytokines, such as *Il2*, *Il6*, and *Tnf*. AhR has been previously shown to inhibit pro-inflammatory IL-17 and IFN-γ cytokine production in T cells and to induce Tr1 cell differentiation in the gut ([@bib73]). In addition, in the absence of AhR in macrophages, mice are more susceptible to LPS-induced endotoxic shock and present with an increase in pro-inflammatory IL-6 expression ([@bib22]). AhR deletion in microglial cells led to the upregulation of *Ccl2*, *Il1b*, *Nos2*, and *Vegfb* gene expression, factors known to be involved in inflammation and neurodegeneration ([@bib47]). Our data reveal that AhR preserves the immunosuppressive function of splenic IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs by silencing a pro-inflammatory transcriptional program. Whether AhR complexes bind to XRE on the loci of pro-inflammatory cytokines and directly inhibit their expression in B cells, or if AhR coordinates the suppression of pro-inflammatory immune responses through interaction with other transcription factors in B cells, warrants further study.

Our adoptive transfer results suggest that the predominant effect of AhR loss in B cells on AIA is through the loss of IL-10. We have previously shown that adoptive transfer of IL-10^−/−^ B cells is unable to suppress arthritis ([@bib6], [@bib10]). Here we show that WT mice do not get worse disease than the PBS control-injected mice upon adoptive transfer of AhR^−^CD19^+^CD21^hi^CD24^hi^ B cells. Equally, AhR^−^CD19^+^CD21^hi^CD24^hi^ B cells do not suppress disease onset in the recipient mice, unlike the transfer of control AhR^+^CD19^+^CD21^hi^CD24^hi^ B cells. These data therefore suggest that the deleterious effects observed in AIA is the consequence of the reduced amount of IL-10. However, we cannot rule out the possibility that *in vivo*, AhR-deficient B cells contribute to overall inflammation through the upregulation of pro-inflammatory cytokines and chemokines or indirectly through the recruitment of other cell types.

We have recently reported that AhR deletion, rather than impairing the capacity of B cells to proliferate, instead compromised their ability to commence the cell cycle ([@bib66]). Indeed, there was reduction in *Ccno* mRNA expression in splenic B cells isolated from naive *Ahr*^*fl/−*^*Mb1*^*cre/+*^ compared with *Mb1*^*cre/+*^ mice. Here we show that this defect is overcome during an arthritogenic response, as no change in Ki-67 expression or in genes regulating the cell cycle, including *Ccno*, were observed between *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells taken directly from arthritic mice. Furthermore, no difference was observed in Ki-67 expression between *Mb1*^*cre/+*^ and *Ahr*^*fl/−*^*Mb1*^*cre/+*^ CD19^+^CD21^hi^CD24^hi^B cells after restimulation with LPS+anti-IgM. Although, in the latter, we used purified CD19^+^CD21^hi^CD24^hi^ B cells instead of total splenic B cells and used different stimuli to activate this population, which together might account for the differences observed in this study. Therefore, these data confirmed that the phenotype observed in the absence of AhR expression in B cells is not due to impaired B cell proliferation but instead is due to the reduced ability of B cells to differentiate into Bregs and reduction in the production of IL-10.

Our results show that although the loss of B cell AhR expression reduces IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg frequency and leads to an expansion of plasma cells, it does not affect the frequencies or absolute numbers of B cell populations up to a mature naive B cell stage. Taken together with previous findings showing that AhR is expressed by B cells from the immature B cell stage in the bone marrow ([@bib66], [@bib69], [@bib70]), we suggest that B cell AhR expression is important primarily for the control of IL-10^+^CD19^+^CD21^hi^CD24^hi^Breg immune-regulatory transcriptional programming and restricting plasma cell development but is dispensable for homeostatic B cell development. We report that *Ahr*^*fl/−*^*Mb1*^*cre/+*^ mice have increased frequencies of splenic plasma cells compared with control *Mb1*^*cre/+*^ mice, and these results are in line with those showing that both prototypic AhR agonists (polycyclic aromatic and planar halogenated hydrocarbons) affect terminal differentiation of B cells and humoral immune responses by inhibiting plasma cell differentiation and reducing the production of IgM ([@bib51], [@bib61], [@bib63]). We find increased levels of *Prdm1* (Blimp-1) mRNA expression in B cells lacking AhR, consistent with previous findings showing that the suppression of terminal differentiation is mediated through AhR increases Bach2 expression ([@bib7]); Bach2 in turn represses the expression of Blimp-1, a key transcription factor that controls B cell differentiation into immunoglobulin-producing plasma cells ([@bib62]). We have extended the significance of these results to an inflammatory model and shown that early B cell development and maturation of B cells is not affected by B cell AhR expression but that AhR is required for the differentiation of IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs. It is tantalizing to propose that the increase in plasma cells observed in mice lacking AhR^+^IL-10^+^CD19^+^CD21^hi^CD24^hi^Bregs is due to the impaired function of Bregs. We have previously shown that at least in humans, IL-10 produced by Bregs directly inhibits T helper cell differentiation, which prevents plasma cell differentiation ([@bib34]).

Here we have shown that AhR, in response to inflammatory signals, plays an important role in the homeostatic maintenance of Breg function by acting as a molecular brake, preventing the differentiation of Bregs into effector B cells producing pro-inflammatory mediators. In addition to identifying that AhR regulates IL-10 expression in Bregs, our data highlight an additional mechanism by which AhR restrains inflammatory responses. These results add to a growing body of evidence supporting AhR as a key modulator of immune tolerance and therefore a potential therapeutic target in autoimmunity.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Professor Claudia Mauri (<c.mauri@ucl.ac.uk>). This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

IL-10eGFP mice were as described ([@bib28]), courtesy of Prof Karp. C57BL/6 mice were from purchased from Envigo, UK. *Ahr*^*−/−*^*, Ahr*^*+/−*^, *Mb1*^*cre/+*^ (courtesy of Prof Reth) and *Ahr*^*fl/-*^*Mb1*^*cre/+*^ mice were kindly provided by Prof. Brigitta Stockinger. IL-10R^−/−^ mice were kindly given courtesy of Professor Werner Muller. Male and female mice were used at 8--12 weeks of age and were bred and maintained at the animal facility, University College London. All experiments were approved by the Animal Welfare and Ethical Review Body of University College London and authorized by the United Kingdom Home Office.

### Induction of antigen-induced arthritis (AIA) {#sec4.3.1}

AIA was induced and assessed as previously described ([@bib46]). Briefly, mice were injected subcutaneously at the tail base with 200 μg of methylated BSA (mBSA; Sigma-Aldrich) emulsified in 100 μL Complete Freund's Adjuvant (CFA). CFA was made by mixing 3mg/ml of *Mycobacterium tuberculosis* (Difco) in Incomplete Freund's Adjuvant (IFA; Sigma-Aldrich). After 7 days, mice received an intra-articular (IA) injection of 10 μL of PBS containing 200 μg mBSA in the right knee and 10 μL PBS alone in the left knee as a control. Joint size was measured using callipers (POCO 2T; Kroeplin GmbH) at daily intervals and swelling was calculated as a percentage increase in size between the inflamed and control knee. All experiments, unless stated otherwise, were performed at day 7 post-IA injection.

Method Details {#sec4.4}
--------------

### Cell isolation and culture {#sec4.4.1}

For splenocyte and lymph node cell preparation, organs were mashed through a 70 μM cell strainer (BD Biosciences), as previously described ([@bib46]), and erythrocytes from spleens were lysed using Red Cell Lysis Buffer (Sigma-Aldrich). B cells were negatively purified by magnetic separation, according to manufacturer's instructions (Miltenyi Biotec). Cells were cultured with either RPMI 1640 (Sigma-Aldrich) containing L-glutamine and NAHCO~3~ or Iscove's Modified Dulbecco's Medium (IMDM; Pan Biotech), enriched in AhR agonists ([@bib65]), supplemented with L-Glutamine and 25mM HEPES. Media were supplemented with 10% fetal calf serum (LabTech), 1% penicillin/streptomycin (100U/ml Penicillin+100 μg/ml streptomycin; Sigma-Aldrich) and 50 μM 2-Mercaptoethanol (ThermoFisher Scientific). Cells were cultured at 37°C with 5% CO~2~.

Total lymphocytes, B cells and B cell subsets were cultured for 48h with CpGb ODN1826 (1 μM; Invivogen), LPS (1 μg/ml; Sigma-Aldrich) ± anti-mouse IgM (10 μg/ml; Jackson ImmunoResearch). or anti-CD40 (10 μg/ml; BioXcell). In addition, AhR agonist FICZ (100nM; Enzo LifeSciences) was added to culture. For 48h culture, anti-IgM ± FICZ were added 24h into culture.

### ELISA's on cell culture supernatants and sera {#sec4.4.2}

Supernatants from cell cultures were harvested and analyzed for cytokines using standard sandwich IL-2, IL-6, IL-10, IL-17 and TNFα ELISA Kits (R&D Systems) and performed according to manufacturer's instructions. Serum was collected from *Mb1*^*cre/+*^ and *Ahr*^*fl/-*^*Mb1*^*cre/+*^ day 7 post AIA and was analyzed for total IgA, IgG and IgM (ThermoFisher Scientific).

### Flow cytometry and cell sorting {#sec4.4.3}

Flow cytometry was performed with the following directly conjugated antibodies from Biolegend: CD1d Percp/Cy5.5 (1B1), CD3 BV605 (17A2), CD4 BV711 (RM4-5), CD5 AF647 (53-7.3), CD19 BV785 (6D5), CD21 APC (CR2/CR1), CD23 FITC (B3B4), CD24 PE-Cy7 or BV421 (M1/69), CD43 PECy7 (S7), CD138 BV711 (281-2) and Tim-1 PE (RMT1-4). CD249 PE (BP-1) was purchased from BD Biosciences. For multi-color flow cytometric surface staining, cells were stained at 4°C for 20 min as previously described ([@bib37]). LIVE/DEAD fixable blue Dead Cell Stain (Life Technologies) was used to exclude dead cells from flow cytometric analysis. For measurement of intra-nuclear Blimp-1, Ki-67 and FoxP3 expression, cells were fixed for 25 minutes with FoxP3 Fixation buffer (ThermoFisher Scientific) and Blimp-1 AF647 (5E7), Ki-67 BV421 (16A8; Biolegend) or FoxP3 APC (FJK-16 s; ThermoFisher Scientific) was added in permeabilisation buffer. Intracellular cytokine analysis was performed as described previously ([@bib46]). Briefly, for detection of IFN-γ, IL-10 and IL-17, splenocyte or lymph node cells were cultured in complete medium with PMA (50ng/ml; Sigma-Aldrich), Ionomycin (250ng/ml; Sigma-Aldrich) and Brefeldin A (5 μg/ml; Sigma-Aldrich) for 4.5h. Cells were then stained with surface markers followed by intracellular fixation and permeabilisation (ThermoFisher Scientific). Cells were incubated with IFN-γ ΑPC (XMG1.2; BD PharMingen), IL-10 PE (JES5-16E3; Biolegend) and IL-17 PE (TC11-18H10.1; BD PharMingen). FP635 and eGFP reporter expression were analyzed *ex vivo* without fixation.

B cell subsets were sorted using a cell sorter (FACSAria; BD PharMingen) by using CD19 BV785, CD21 APC, CD23 FITC and CD24 PE-Cy7. Dead cells were excluded by the use of 4,6-diamidino-2-phenylindole at 1 μg/ml (DAPI; Sigma). For cell sorting for RNA-seq and ATAC-seq, addition of BV605 dump channel antibodies against CD3 (17A2), CD4 (RM4-5), CD8a (53-6.7), CD11b (M1/70), CD11c (N418), F4/80 (BM8), Ly6C/G (RB6-8C5), erythroid cells (TER-119) and TCRβ (H57-597) were incorporated (Biolegend). Sort purity of B cell subpopulations was routinely \> 95%. Flow cytometric data were collected on an LSRII or LSR Fortessa (BD PharMingen) using FACS Diva software. Data were analyzed using Flowjo (Tree Star).

### In-vitro suppression assay {#sec4.4.4}

Splenic B cell subsets from *Ahr*^*−/−*^ and *Ahr*^*+/−*^ mice were sorted at day 7 post IA injection and stimulated with CpGb (ODN2006) for 6 hours. Cells were washed and then co-cultured with 0.5 μg/ml plate-bound anti-CD3 (145-2C11, BD Biosciences) for 72 hours with CD4^+^CD25^-^ (bead isolated) T cells from *Ahr*^*+/−*^ mice. Following stimulation, cells were analyzed for CD4^+^ IFN-γ expression. The percentage suppression of IFN-γ was calculated as a percentage reduction in IFN-γ from CD4^+^ cells cultured alone, compared to when B cell subsets were added to culture.

### Adoptive transfer experiments {#sec4.4.5}

CD19^+^CD21^hi^CD24^hi^ B cells were isolated from spleens of *Mb1*^*cre/+*^ and *Ahr*^*fl/-*^*Mb1*^*cre/+*^ mice after remission from AIA and 5x10^6^ were transferred into recipient wild-type mice on the day of intra-articular injection. The control group (no transfer) received a PBS injection.

### Histology {#sec4.4.6}

For histopathological examination, joints from *Ahr*^*fl/-*^*Mb1*^*cre/+*^ and *Mb1*^*cre/+*^ mice were removed post-mortem and fixed in 5% formalin and decalcified in 5% EDTA. The fixed joints were embedded in paraffin and 4 μm sections were cut and stained with hematoxylin-eosin.

### Microarray analysis and RNA extraction {#sec4.4.7}

Splenic B cell subsets were sorted and RNA extracted using columns (Picopure, Life Technologies) and hybridized to murine mogene 2.0 ST arrays (Affymetrix). Raw CEL files were processed using the online GeneProfiler tool (accessible at <https://www.beringresearch.com>). Briefly, the GeneProfiler pipeline consists of present/absent call detection, ([@bib33]) Robust Microarray Average (RMA) normalization, and outlier detection ([@bib20]). Differential expression analysis was performed using the *limma* package ([@bib42]).

### Chromatin Immunoprecipitation {#sec4.4.8}

Total Vert-X splenic B cells were bead cell sorted and cultured for 24h with LPS, followed by addition of anti-IgM (10 μg/ml) and FICZ (100nM) at 24h into culture. After 48h total, total B cells were sorted based on eGFP for IL-10^+^ and IL-10^-^ populations. Cells were fixed for 10 minutes with 1% (vol/vol) formaldehyde and quenched with 400mM Tris. Fixed cells were lysed with 120 μL lysis buffer (1% (wt/vol) SDS, 10mM EDTA and 50mM Tris-HCl, pH 8.1, 1 × protease inhibitor 'cocktail' (Roche), 1mM PMSF) per 5x10^6^ cells. Chromatin was sheared to 200-500bp fragments and 10% of the initial chromatin material was kept as input. The chromatin was diluted 5-fold in Dilution Buffer (1% (vol/vol) Triton X-100, 2mM EDTA, 150mM NaCl and 20mM Tris-HCl, pH 8.1) and incubated overnight, after preclearing, with 1 μg/10^6^ cells of a polyclonal AhR-specific antibody (BML-SA210; Enzo Life Sciences). Immunoprecipitation took place by incubation with protein G Dynal magnetic beads (Invitrogen), held for at least 3 hours at 4°C. Immunoprecipitated chromatin complexes were washed with High Salt Wash Buffer (2x), Low Salt Wash Buffer (2x), LiCl Wash Buffer (2x) and TE Buffer (2x). Immunoprecipitated chromatin was eluted from the magnetic beads with Proteinase K Digestion Buffer and heated at 65°C for at least 6h for reverse crosslinking. DNA fragments were purified with NucleoMag beads kit (MN) and were analyzed by SYBR Green Quantitative Real-time PCR. The following primers were used for ChIP qPCR: *Il10* −3.5kb forward (5′-AGGGCTTGATAACGTGTGAGT-3′); *Il10* −3.5kb reverse (5′-TGAACTTCACACCCAGCTTGAG-3′); *Il10* −2kb forward (5′-TAAGAGGTGCTGCTTCTCCTG-3′); *Il10* −2kb reverse (5′-TGGCACTGGACAGTTCTATGA-3′); *Il10* −0.5kb forward (5′-AGGGAGGAGGAGCCTGAATAA-3′); *Il10* −0.5kb reverse (5′-CCTGTTCTTGGTCCCCCTTTT-3′); *Il10* +2kb forward (5′-GCCACATGCATCCAGAGACAC-3′); *Il10* +2kb reverse (5′-GTGCCTCAAAGTCACTCCCAC-3′); *Cyp1a1* −3.6kb forward (5′-GCTCTTTCTCTGCCAGGTTG-3′); *Cyp1a1* −3.6kb reverse (5′-GGCTAAGGGTCACAATGGAA-3′); *Cyp1a1* promoter forward (5′-AAGCATCACCCTTTGTAGCC-3′); *Cyp1a1* promoter reverse (5′-CAGGCAACACAGAGAAGTCG-3′); *Gapdh* promoter forward (5′-GCGCGAAAGTAAAGAAAGAAGCCC-3′); *Gapdh* promoter reverse (5′-AGCGGCCCGGAGTCTTAAGTATTAG-3′).

### Western blot {#sec4.4.9}

5x10^6^ cells CD19^+^CD21^hi^CD24^hi^ and FO B cells were FACS sorted from arthritic WT mice and lysed for 15 minutes at 4°C with cell lysis buffer (Cell signaling technology) for extraction of whole cell lysate. Protein was resolved by SDS-PAGE, transferred to nitrocellulose membranes and blotted using anti-AhR at 1/1000 (Enzo Life sciences) and anti-β-actin at 1/1000 (Cell Signaling Technology). Bound antibodies were revealed with a goat-anti rabbit H&L HRP-conjugated secondary antibody (1/1000) and ECL western blotting substrate (ThermoFisher Scientific).

### RNA-seq {#sec4.4.10}

Splenic CD19^+^CD21^hi^CD24^hi^ B cells were isolated from *Mb1*^*cre*^ and *Ahr*^*fl/-*^*Mb1*^*cre*^ mice in the remission phase of arthritis, at day 7 post-IA injection. Sorted cells were either left untouched (*ex-vivo*) or stimulated with LPS+anti-IgM for 6h in IMDM media. Dead cells were excluded using DAPI. Total RNA was isolated from these populations using the Picopure RNA isolation kit (ThermoFisher Scientific), according to manufacturer's instructions. 60bp single reads were sequenced on 3 lanes of an Illumina hiseq. 130-500ng of total RNA was fragmented followed by reverse transcription and second strand cDNA synthesis. The double strand cDNA was subjected to end repair, A base addition, adaptor ligation and PCR amplification to create libraries. Libraries were evaluated by Qubit and TapeStation. Sequencing libraries were constructed with barcodes to allow multiplexing of samples in 3 lanes. Around 23-43 million single-end 60-bp reads were sequenced per sample on an Illumina HiSeq 2500 V4 instrument.

Poly-A/T stretches and Illumina adapters were trimmed from the reads using cutadapt. Resulting reads \< 30bp were discarded. Reads were mapped to the *Mus musculus* GRCm38 reference genome using STAR ([@bib9]). Gene annotations were applied from Ensembl (EndToEnd option and outFilterMismatchNoverLmax was set to 0.04). Gene expression levels were quantified using htseq-count ("HTSeq," n.d.) ([@bib1]), using the gtf above. Transcripts per million (TPM) values were estimated independently using Kallisto ([@bib4]).

### Bioinformatic analysis of RNA-seq data {#sec4.4.11}

Differential expression analysis was performed using the default settings of the edgeR algorithm ([@bib44]). p values reflect two-sided p values obtained using the exact test proposed by Robinson and Smyth ([@bib43]) for a difference in means, between two groups of negative binomial random variables (implemented in edgeR package). Signaling Pathway Impact Analysis (SPIA) ([@bib57]) was used to detect significantly over-represented pathways, with the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathways database ([@bib18]) employed as a reference. The full mouse genome was used as background for enrichment.

### ATAC-seq {#sec4.4.12}

ATAC-seq was performed on splenic IL-10eGFP^+^CD19^+^CD21^hi^CD23^hi^CD24^hi^, IL-10eGFP^-^CD19^+^CD21^hi^CD23^hi^CD24^hi^ and IL-10eGFP^-^FO B cells. In addition, ATAC-seq was performed on splenic total CD19^+^CD21^hi^CD24^hi^ B cells isolated as above for the RNA-seq from *Mb1*^*cre/+*^ and *Ahr*^*fl/-*^*Mb1*^*cre/+*^ mice either left untouched (ex-vivo) or stimulated with LPS+anti-IgM for 6h in IMDM media. After sorting, 40,000 were washed with 1xPBS (10% FCS). The cell pellet was prepped for sequencing by using the Nextera DNA library preparation kit (Illumina). Briefly, 10.5 μL nuclease free water, 12.5 μL 2x Transposase buffer, 2 μL transposase and 0.25 μL digitonin (0.05%) per reaction were added to the cell pellets. Cells were incubated at 37°C for 30 minutes. DNA was then purified using a MinElute PCR purification kit (QIAGEN), according to manufacturer's instructions. Following DNA purification, 1μl of eluted DNA was used in a qPCR reaction to estimate the optimum number of amplification cycles. Library amplification was performed using custom Nextera primers and was followed by solid phase reversible immobilization (SPRI) size selection to exclude fragments larger than 1,200bp. DNA concentration was measured with a Qubit fluorometer (Life Technologies). The libraries were sequenced by the Biomedical Sequencing Facility at CeMM using the Illumina HiSeq4000 platform and the 50bp single-end configuration.

### Bioinformatic analysis of ATAC-seq data {#sec4.4.13}

Bioinformatic analysis was performed as previously described ([@bib40]). Briefly, Illumina Casava1.7 software was used for basecalling. Sequenced reads were trimmed for adaptor and Nextera sequences and reads were mapped to mm10 reference genome using bowtie2 v2.2.4 with the "--very-sensitive" parameter. Duplicate reads were marked and removed with picard tools version 1.118. Reads were extended to the average fragment size and bigWig files containing counts of reads per basepair created. Peaks for ATAC-seq samples were called with MACS2 version 2.1.1.20160309 ([@bib75]) using the "--nomodel" and "--extsize 147" parameters. Peaks were assigned to genes by proximity. If a peak overlapped the gene body or promoter ± 2500bp of the transcription start site (TSS), the peak was assigned to that gene. If a peak did not fall into these criteria, the peak was assigned to the closest TSS. If the nearest TSS to the peak was further than 100kb away, no gene was assigned.

### qPCR {#sec4.4.14}

qPCR analyses were performed as described ([@bib37]). RNA from isolated B cells/subsets was extracted using Arcturus Picopure RNA isolation kit (ThermoFisher Scientific) and RNA was reverse transcribed using an iScript cDNA synthesis kit (Bio-Rad), according to manufacturer's instructions. qPCR was performed on the cDNA samples using iQ SYBR® Green Supermix (Bio-Rad), according to manufacturer's instructions. Primers were used at a concentration of 10 μM. Quantitect primers for *Arnt*, *Ahrr* and *Cyp1a1* were purchased from QIAGEN. Primers for *β-Actin* and *Ahr* were custom designed with the following sequences: *Act* Forward (5′-AGATGACCCAGATCATGTTTGAG-3′); *Act* Reverse (5′- AGGTCCAGACGCAGGATG-3′); *Ahr* Forward (5′-AGGATCGGGGTACCAGTTCA-3′); *Ahr* Reverse (5′-CTCCAGCGACTGTGTTTTGC-3′); *Il6* Forward (5′-GCCTTCTTGGGACTGATGCT-3′); *Il6* Reverse (5′-TGCCATTGCACAACTCTTTTC-3′); *Il5ra* Forward (5′-GGTCCCGGTATGCAGTTCTA-3′); *Il5ra* Reverse 5′-AGCCGAATGCTGGAAAAGTG-3′. *Ccl22* ([@bib14]), *Ebi3* ([@bib52]), *Il2* ([@bib29]), *Il10* ([@bib72]), *p35* ([@bib52]) *Tnf* ([@bib8]) were used as previously described. qPCR data were calculated as the ratio of gene to *β-*Actin expression by the relative quantification method (ΔΔC~t~; means ± s.e.m. of triplicate determination).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Heatmap analyses for microarray, RNA-seq and ATAC-seq datasets were performed using Multiple Experiment Viewer (MeV_4\_8) software ([@bib49]). Hierarchical clustering was applied to genes using average linking clustering with the Euclidean distance metric. All data are expressed as mean ± s.e.m, unless stated otherwise. For *in vivo* studies, power calculations were performed on data showing mean maximum wild-type arthritic knee swelling of 2 mm with a s.d. of 0.39 mm, and an expected test group (transferred T2-MZPs) arthritic knee swelling of 1.4 mm. Group sizes of three mice or above were sufficient to reach a statistical power of at least 80% (<http://www.statisticalsolutions.net/pss_calc.php>). Mice were assigned at random to treatment groups for all mouse studies and, where possible, mixed among cages. Clinical scoring was performed in a blinded fashion. Mice that developed adverse reactions to protocols were excluded from datasets. Statistical significance was determined using unpaired t tests (comparison of two groups), using mann-whitney tests (comparison of two groups, non-parametric data), one-way ANOVA (comparison of three or more groups) or two-way ANOVA (comparison of two or more groups with 2 independent variables). One and two-way ANOVA were assessed with Bonferonni's multiple comparison tests. All data met the assumption of statistical tests and had a normal distribution and variance was similar between groups that were statistically compared. Results were considered significant at p ≤ 0.05. Statistical tests were performed using GraphPad Prism (La Jolla, CA, USA) v.6, Software for Apple Mac.

Data and Code Availability {#sec4.6}
--------------------------

The microarray, RNA-seq and ATAC-seq datasets generated during this study are available at ArrayExpress: [E-MTAB-7345](array-express:E-MTAB-7345){#interref265}, [E-MTAB-7375](array-express:E-MTAB-7375){#interref270}, [E-MTAB-7525](array-express:E-MTAB-7525){#interref275} and [E-MTAB-8393](array-express:E-MTAB-8393){#interref280}.
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